Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study by Rongve, Arvid et al.
Cognitive decline in dementia with
Lewy bodies: a 5-year prospective
cohort study
A Rongve,1,2 H Soennesyn,3 Ragnhild Skogseth,4 Ragnhild Oesterhus,3
T Hortobágyi,5,6 Clive Ballard,6 B H Auestad,7 D Aarsland3,8
To cite: Rongve A,
Soennesyn H, Skogseth R,
et al. Cognitive decline in
dementia with Lewy bodies: a
5-year prospective cohort
study. BMJ Open 2016;6:
e010357. doi:10.1136/
bmjopen-2015-010357
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
010357).
Received 23 October 2015
Revised 25 January 2016
Accepted 11 February 2016
For numbered affiliations see
end of article.
Correspondence to
Dr A Rongve;
arvid.rongve@helse-fonna.no
ABSTRACT
Objectives: We report the cognitive decline in
persons diagnosed with mild dementia with Lewy
bodies (DLB) and mild Alzheimer’s disease (AD) during
5 years of annual follow-ups.
Methods: Patients were recruited into the study from
geriatric, psychiatric and neurology clinics in Western
Norway during 2005–2013. They were diagnosed
according to clinical consensus criteria, based on
standardised clinical rating scales. Autopsy-based
diagnoses were available for 20 cases. Cognitive
decline for up to 5 years was assessed using the
Clinical Dementia Rating (CDR) scale and the Mini-
Mental State Examination (MMSE). Survival analysis
including Cox regression (time to reach severe
dementia) and linear mixed-effects (lme) modelling
were used to model the decline on MMSE.
Results: At least one follow-up assessment was
available for 67 patients with DLB and 107 patients
with AD, with a median follow-up time of 4.3 years.
The time to reach severe dementia was significantly
shorter in DLB (median 1793 days) compared with
AD (1947 days; p=0.033), and the difference remained
significant in the multiple Cox regression analysis
(HR=2.0, p<0.02). In the adjusted lme model, MMSE
decline was faster in DLB (annual decline 4.4 points)
compared with AD (3.2 points; p<0.008).
Conclusions: Our findings show that from the mild
dementia stage, patients with DLB have a more rapid
cognitive decline than in AD. Such prognostic
information is vital for patients and families and crucial
for planning clinical trials and enabling health
economic modelling.
INTRODUCTION
Few longitudinal cohort studies of dementia
with Lewy bodies (DLB) exist compared with
in other neurodegenerative diseases.1 2
Accordingly, the long-term course and prog-
nostic factors in DLB are not known. Early
observations suggested that patients with
DLB had a faster cognitive decline as
compared with Alzheimer’s disease (AD),3
but subsequent studies have reported
contradictory results. In a recent
meta-analysis, we found no signiﬁcant differ-
ence in the rate of decline on Mini-Mental
State Examination (MMSE) in DLB and AD.4
However, this conclusion was based on few
studies with small sample sizes and short
follow-up time. Understanding the disease
course is vital to give patients and families a
better understanding of prognosis and is also
essential to underpin accurate design and
powering of clinical trials and to enable
health economic models for cost-
effectiveness. We therefore aimed to assess
the rate of decline for up to 5 years in DLB
in comparison to AD. In addition to the
MMSE, which may be less sensitive to the
cognitive changes in DLB compared with
AD,5 we used a broader assessment of cogni-
tion and function, the Clinical Dementia
Rating (CDR) scale,6 using time to reach
severe dementia, CDR stage 3, as a co-
primary outcome.
METHODS
Design
We used a prospective design, and patients
with DLB were diagnosed clinically using
extensive and standardised diagnostic investi-
gations and also recruiting for postmortem
Strengths and limitations of this study
▪ We report the largest dementia with Lewy bodies
(DLB) cohort with the longest follow-up to date.
▪ We followed all included participants every
12 months until study end or death.
▪ We applied highly standardised diagnostic proce-
dures including the Mayo fluctuation and Mayo
sleep scales to diagnose DLB.
▪ We provide autopsy-proven diagnoses for 9% of
included cases.
▪ Clinical dementia diagnoses were revised after
5 years of annual follow-ups based on all avail-
able information.
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conﬁrmation. Our aim was to allow for long follow-up
time from the time of diagnosis with annual assessment
points. There is yet no consensus regarding the best cog-
nitive scale to track cognitive decline in DLB, and thus
we used CDR as our measure of cognitive functioning.
Participants and inclusion
In the Dementia Study of western Norway
(DemVest-study) all referrals to geriatric and psychiatric
clinics in Hordaland and Rogaland counties (with 448
343 (13.4% aged 67 or higher) and 393 104 (11.5%,
67+) inhabitants, respectively) underwent a full medical
examination for a ﬁrst-time diagnosis of mild dementia
during 2005–2007, and consecutively invited to partici-
pate if inclusion and exclusion criteria were fulﬁlled. All
neurology clinics in the region were invited to refer
patients with suspected dementia to the study. The refer-
ral pattern varies among general practitioners (GPs),
but most dementia patients are diagnosed by their local
GP. To reduce risk for referral bias, GPs in the area were
therefore contacted by letter prior to study start and
invited to refer all patients with suspect dementia to one
of the participating centres. Subsequently we included
DLB cases selectively from 2007 until 2013 to increase
sample size.7 Patients were followed annually with a
structured interview, caregiver interview and cognitive
tests. Drug treatment was provided as clinically indicated
by the treating physician, but it was recommended that
patients with AD and DLB should receive treatment with
cholinesterase inhibitor, and most patients were treated
from inclusion in the study.
Inclusion and exclusion criteria
To select patients with mild dementia only, a MMSE
score of at least 20 or a CDR global score=1 was required
for inclusion. Patients without dementia or with acute
delirium or confusion, terminal illness, recently diag-
nosed with a major somatic illness which according to
the clinician would signiﬁcantly impact on cognition,
function or study participation, previous bipolar dis-
order or psychotic disorder were excluded. Patients were
recruited for brain donation and subsequent patho-
logical diagnosis. Only patients with probable or deﬁnite
DLB and AD were included in this study.
Diagnostic and clinical baseline examination
A research clinician performed a structured clinical
interview of patients and caregivers regarding demo-
graphics, previous diseases and drug history. The assess-
ment procedure included a detailed history using a
semistructured interview, clinical examination including
physical, neurological, psychiatric and a detailed neuro-
psychological test battery, routine of blood and brain
MRI. Dopamine transporter SPECT scans were available
for 34 patients with DLB, and was clearly abnormal in 26
and borderline in 2 cases. The ﬁnal clinical diagnosis
was made by two of the study clinicians based on all
available information, including pathological diagnosis
when available, according to the consensus criteria for
DLB and AD.8 9 The diagnoses were re-evaluated several
times during the study period, and a ﬁnal diagnosis was
made in 2014 (see ref. 7 for further details of the inclu-
sion and diagnostic and baseline procedures). A patho-
logical diagnosis was available in 20 patients (see below).
Structured rating scales for detecting the DLB core fea-
tures were systematically administered to all patients by
dedicated study physicians or research nurses. Annual
meetings between study clinicians were held to maintain
similar procedures. Fluctuating cognition was rated using
the Clinician Assessment of Cognitive Fluctuations10 or
the Mayo Fluctuation Questionnaire.11 REM sleep behav-
iour disorder (RBD) was diagnosed if there was a history
of recurrent nocturnal dream enactment behaviour
recorded from the Mayo Sleep Questionnaire (MSQ).12
The Uniﬁed Parkinson’s Rating Scale item 3
(UPDRS-3)13 was used to measure parkinsonian symp-
toms. Activities of daily living were assessed using the
Rapid Disability Rating Scale-2.14 The Neuropsychiatric
Inventory (NPI) was applied to assess visual hallucina-
tions and other psychiatric symptoms.15 The Cumulative
Illness Rating Scale (CIRS)16 was applied to measure the
total burden of all other diseases.
Cognitive decline
Cognitive decline was measured using the CDR scale.
The CDR examines six different areas in dementia:
memory, orientation, judgement and problem solving,
community affairs, home and hobbies, and personal
care. All six items are scored from 0 to 3, with 0 corre-
sponding to no dementia, 0.5 mild cognitive impairment,
1 mild dementia, 2 moderately severe dementia and 3
severe dementia. A global score 0–3 was calculated based
on an available online algorithm. The time from baseline
to the ﬁrst assessment with an overall CDR score of 3, that
is, severe dementia, was recorded. The CDR was scored
by a trained research physician, and the scoring was
made independent of the other cognitive tests, by the
same clinician at every occasion to the extent possible. In
addition, cognition was also measured using the MMSE,
administered by a trained research nurse. Decline was cal-
culated from baseline to study end, death or ﬁrst assess-
ment with MMSE score equal to 0.
Pathological diagnosis and APOE genotyping
Brain dissection, regional sampling, and tissue process-
ing and staining are done following standard protocols
including BrainNet Europe and Brains for Dementia
Research UK.17 18 Speciﬁc stain for identiﬁcation of
AD-type and LB pathologies (modiﬁed Bielschowsky),
and immune histochemical procedures were used for
detection of hyperphosphorylated τ (pretangles, tangles,
dystrophic neurites and neuropil threads), amyloid β
(diffuse and classical plaques and amyloid angiopathy),
and α-synuclein (LB and Lewy neurites), according to
standard immunohistochemical protocols. Each case was
assessed by an experienced neuropathologist (TH) who
2 Rongve A, et al. BMJ Open 2016;6:e010357. doi:10.1136/bmjopen-2015-010357
Open Access
group.bmj.com on March 8, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
was blinded to clinical data. Pathological diagnosis was
made according to international consensus criteria for
DLB8 and AD.8 17 19–21 The presence of possible coexist-
ing TAR DNA-binding protein 43 (TDP-43) proteinopathy
was assessed according to guidelines,22 and microscopic
vascular lesions considered and recorded.23 A neuro-
pathological diagnosis was available for a total 20 of the
included patients.
APOE genotyping was performed in 125 patients,24
and the proportion with at least one e4 allele was 64% in
both groups.
Statistics
Baseline characteristics are presented and group compari-
sons made using t test, Mann-Whitney or χ2 tests as appro-
priate. We applied Kaplan-Meyer survival analysis and the
log-rank test. Time to CDR=3 was analysed and compared
between the groups using Cox regression analysis, and
clinical predictors of course were identiﬁed. These data
have some indication of non-proportional hazards at
about 5 years which may lead to unreliable results. To
avoid problems caused by this, we partitioned the time axis
by censoring at 5 years as suggested in chapter 6 of
Therneau and Grambsch.25 The cox regression was per-
formed using these extra censored data. This removed
signs of possible non-proportional hazards according to
tests based on scaled Schoenfeldt residuals. We also ana-
lysed time to CDR=3 or death as a clinically relevant
outcome. Longitudinal analysis with linear mixed-effects
(lme) model, adjusting for age, sex, CIRS, duration and
baseline MMSE, and CDR was applied using random inter-
cept and slope model. This produced an adequate model
for the data according to analyses of the residuals and
random effects. Need for interaction terms in the model
was checked with clear non-signiﬁcant results. Possible
non-linear patterns in decline were checked by adding a
time squared term to the model. This was also clearly insig-
niﬁcant. It may be argued that the more frequent
drop-out in the DLB group due to death as compared with
the AD group occur at random26 and thus the lme model-
ling approach adjusts for this in an appropriate way in this
situation. To study the impact of different death rates on
longitudinal outcome, we also tried joint modelling where
the lme model is linked to a cox proportional hazards
model for survival. Although a signiﬁcant correlation
between death rates and longitudinal outcome was regis-
tered, this death rate-adjusted lme analysis showed practic-
ally the same results as the ordinary lme analysis. All
statistical analyses were performed using the program
packages SPSS and R. (Team RC. A language and environ-
ment for statistical computing. Vienna, Austria: R
Foundation for Statistical Computing; 2013. URL http://
www R-project org).
RESULTS
Follow-up data were available for 107 patients with prob-
able or deﬁnite (n=12) AD and 67 with probable or
deﬁnite (n=8) DLB (see ﬁgure 1). Demographic and
clinical baseline characteristics are shown in table 1.
Patients with DLB were more commonly males, had
slightly longer disease duration, and as expected higher
NPI and UPDRS motor scores. Patients with DLB also
had higher CIRS scores than the AD group. Duration of
follow-up varied according to time of study inclusion
and time of death. One hundred and eleven of the
patients died, but there were no drop-outs for other
reasons. Median follow-up time was 1577 days
(4.3 years), and the number of person-years was 232 for
DLB and 479 for AD. Seventy-one (40.8%) patients
reached a global CDR score of 3, 28 (41.8%) diagnosed
with DLB and 43(40.2%) diagnosed with AD (p=0.834).
The median time to severe dementia, deﬁned as
CDR=3, was 1947 days in AD and 1793 days in DLB
(p=0.033; see ﬁgure 2). The mortality rates were signiﬁ-
cantly higher in DLB than in AD. As can be seen in
ﬁgure 3, there were large variability in the cognitive
decline, some having a short time to reach the severe
dementia stage whereas others remained at the mild or
moderate stage for several years. The unadjusted and
adjusted Cox models (table 2) show that a diagnosis of
DLB was associated with shorter time to severe dementia
Figure 1 Flowchart showing screening and inclusions.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies;
DSM-IV, Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition.
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(HR 2.35, p<0.002 and 2.04, p=0.020). Median time
until CDR=3 or death was1861 days in probable AD and
1210 days in probable DLB (p<0.0005; see ﬁgure 4). In
the fully adjusted Cox regression model, higher baseline
age, longer duration of symptoms and higher CDR
global scores predicted shorter time until CDR=3 or
death in addition to having a DLB diagnosis (p=0.039;
see online supplementary material).
The progression of MMSE is shown in ﬁgure 3. There
is a signiﬁcant decline in MMSE score over time. The
diagnosis X time (years) interaction is signiﬁcant
(p=0.008; table 3), indicating that the decline over time
differs between the two groups. In the adjusted linear
mixed model, taking into account potential confounders
(see table 3), MMSE is reduced on average by 3.2 points
per year in the AD group, whereas in the DLB group, the
decrease is more rapid; on average 4.4 points per year.
The slope is also signiﬁcantly affected by baseline MMSE
level and baseline CDR global scores. The individual and
mean group MMSE scores over the study period are
shown in ﬁgure 3. Figure 3 also illustrates the variability
in the rate of decline, which is slightly higher in DLB (SD
of annual decline 2.2, range −5.9 to 4.1) compared with
AD (SD 1.6, range −4.1 to 3.3). We conducted the lme
analysis also including antidementia drug use in the
model, which was not associated with decline and did not
change the main ﬁndings (results not included).
Among the 20 patients with neuropathological ana-
lysis, seven of the nine with a clinical diagnosis of DLB
had their diagnosis conﬁrmed neuropathologically,
whereas two were changed to AD. In addition, one
patient with a clinical diagnosis of AD was changed to
DLB. Coexisting moderate or severe AD pathology was
present in most of these cases. Ten of the 11 patients
with clinical diagnosis of AD had their diagnosis con-
ﬁrmed with severe AD pathology (Braak τ stage 6),
although some degree of coexisting DLB pathology was
noted in 4, and 3 patients had mild TDP-43 pathology
limited to the amygdala.
Figure 2 Survival until severe dementia in dementia with
Lewy bodies (DLB) and Alzheimer’s disease (AD).
Figure 3 Longitudinal declines on individual MMSE scores
and estimated lme-results. AD, Alzheimer’s disease; DLB,
dementia with Lewy bodies; MMSE, Mini-Mental State
Examination.
Table 1 Baseline characteristics of the cohort
Probable AD (n=107) Probable DLB (n=67) p Value
Age 75.1 (7–9) 76.1 (7–2) 0.598
Female, N (%) 80 (74.8) 32 (47.8) <0.0005
Education, years, mean, SD 9.8 (3.0) 9.5 (2.7) 0.512
CDR global score, median, IQR 1.00 (0.50) 1.00 (0.50) 0.217
MMSE total score, mean, SD 23.6 (2.3) 23.5 (3.0) 0.870
Duration of symptoms before baseline, years, mean, SD 2.0 (2.0) 2.6 (1.9) 0.011
NPI total scores, mean, SD 15.7 (16.9) 22.8 (19.1) 0.006
CIRS score, mean, SD 5.1 (2.1) 6.3 (2.6) 0.004
UPDRS III scores, mean, SD 1.5 (2.3) 14.2 (13.0) <0.0005
Antipsychotics, N (%) 4 (3.7) 10 (14.9) 0.008
Antiparkinsonian medication, N (%) 0 (0) 9 (13.4) <0.005
Antidementia medication, N (%) 68 (63.6) 38 (56.7) 0.436
Death during follow-up, N (%) 59 (55.1) 52 (77.6) 0.003
AD, Alzheimer’s dementia; CDR, Clinical Dementia Rating; CIRS, Cumulative Illness Rating Scale; DLB, Dementia with Lewy bodies; MMSE,
Mini-Mental State Examination; N, number; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale-motor
subscale.
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DISCUSSION
In the largest prospective longitudinal long-term cohort
study in DLB to date, the time to reach severe dementia
was shorter, and the rate of cognitive decline was faster,
in DLB than in AD. This adds to previous ﬁndings that
patients with DLB have a particularly severe prognosis,
including more reduced quality of life,27 higher
health-related costs,28 shorter time to nursing home
admission,29 more severe caregiver burden30 and shorter
survival31 than patients with AD, all factors which are
also crucial for health economic modelling. However,
compared with these outcome measures, the difference
in cognitive decline is less striking, suggesting that
aspects other than the rate of cognitive decline are
more important for clinical milestones such as nursing
home admission and death. Finally, unlike other studies,
we used a different outcome (time to CDR=3) also in
applying a more sophisticated statistical approach.
Previous studies comparing the cognitive course in
DLB and AD have shown inconsistent results. In a
recent systematic review, we identiﬁed 18 longitudinal
studies.4 Some studies reported no difference in the rate
of cognitive decline, whereas some reported faster
decline in DLB and others a faster decline in AD. In
addition, there seemed to be differential decline of the
different cognitive domains, with more rapid memory
decline in AD, and more rapid executive (verbal
ﬂuency) in DLB. In a meta-analysis including the six
studies reporting decline on MMSE, no signiﬁcant differ-
ences were found between AD and DLB. However, these
18 studies were based on small DLB groups and had a
short follow-up period, which may lead to insecure esti-
mates of decline. In addition, several studies included
patients who were already at a moderate or severe
degree of dementia, which may also inﬂuence the rate
of subsequent decline.
Although our cohort is the largest prospectively
studied DLB cohort, the number of patients is neverthe-
less small and thus statistical power to detect differences
is limited. In addition, the relatively high mortality in
DLB leads to few patients completing the full 5-year
observation period. DLB is a heterogeneous disease and
patients may thus be referred to clinics of different
medical specialties, including psychiatry, neurology, geri-
atric medicine and sleep medicine. Since it is possible
that the symptom proﬁle may be related to rate of
decline, ﬁndings from different studies may vary accord-
ing to recruitment procedures. The inclusion of referrals
compared with community-based patients likely lead to
Table 2 Factors associated with time to reach severe dementia
Unadjusted HRs p Value Adjusted HRs p Value
Age at baseline, years 1.00 (0.97 to 1.04) 0.781
Diagnoses, DLB vs AD 2.35 (1.39 to 3.99) 0.002 2.04 (1.12 to 3.72) 0.020
Sex, females vs males 0.6 (0.35 to 1.02) 0.057 0.83 (0.45 to 1.53) 0.556
Education in years 1.01 (0.92 to 1.10) 0.907
Duration of symptoms in years 1.13 (1.00 to 1.27) 0.048 1.15 (1.01 to 1.29) 0.030
MMSE total scores 0.79 (0.71 to 0.89) <0.0005 0.82 (0.73 to 0.93) 0.002
CIRS total scores 1.02 (0.90 to 1.16) 0.745
CDR global scores 3.26 (1.80 to 5.89) <0.0005 2.42 (1.26 to 4.65) 0.008
Cox regression, time until CDR=3. HRs presented with 95% CI.
AD, Alzheimer’s dementia; CDR, Clinical Dementia Rating; CIRS, Cumulative Illness Rating Scale; DLB, Dementia with Lewy bodies; MMSE,
Mini-Mental State Examination.
Figure 4 Survival until severe dementia or death in
Alzheimer’s disease (AD) and dementia with Lewy bodies
(DLB).
Table 3 Factors associated with the rate of decline on
MMSE
Coefficient p Value
Follow-up time in years −3.20 (−3.69, −2.7) <0.0005
Diagnosis 1.63 (0, 3.27) 0.050
Sex 0.41 (−1.01, 1.83) 0.571
Age in years 0.04 (−0.05, 0.13) 0.402
CIRS scores at baseline −0.01 (−0.3, 0.29) 0.957
Duration of symptoms
before baseline in years
−0.10 (−0.41, 0.21) 0.524
MMSE scores at
baseline
0.83 (0.58, 1.08) <0.0005
CDR at baseline −2.48 (−4.16, −0.8) 0.004
Diagnosis x year −1.24 (−2.15, −0.32) 0.008
Linear mixed effects analysis, covariate adjusted.
CDR, Clinical Dementia Rating; CIRS, Cumulative illness rating
scale; ; MMSE, Mini-Mental State Examination.
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more complex AD and DLB cases to be included which
may have inﬂuenced the ﬁndings, and thus our conclu-
sions may not be valid for community-based patients.
Furthermore, we took care to include patients from a
variety of specialist sources; the main recruitment was
from old age psychiatry and geriatric medicine clinics.
Neurology clinics were recommended to refer patients
to the study, but patients with more severe motor symp-
toms may still be under-represented, and no patients
were referred from internal medicine or sleep clinics.
Thus, patients with DLB with primary sleep or autono-
mous symptoms may not have been included.
We used time to severe dementia as measured by CDR
in addition to MMSE as outcome measure. MMSE is less
sensitive to the cognitive impairment associated with
DLB,32 although may still be sensitive to the rate of
change in these patients.33 In contrast, the CDR cap-
tures the full range of functional deﬁcits due to cogni-
tion as judged by a trained clinician after interviewing
patients and caregivers, and is likely a more accurate
and comprehensive measure of severity. However, the
CDR was developed for use in AD and has not yet been
adequately tested in DLB.
Finally, for the majority of patients, a clinical diagnosis
was used, which is not 100% accurate. However, we used
DaTSCAN/CIT-SPECT to help in the differentiation
between DLB and AD, as well as standardised rating
scales for the core and suggestive clinical features of
DLB. The longitudinal assessment by the same clinician
also increases the diagnostic accuracy. In addition,
neuropathological analysis was available for 20 (11%)
cases which conﬁrmed the clinical diagnosis in most
cases. Antidementia medications like cholinesterase inhi-
bitors and memantine improve cognition in both DLB
and AD, but this effect may be longer lasting in DLB as
compared with in AD, and the cognitive decline in DLB
therefor may be underestimated in our study.34
Parkinsonism in DLB might inﬂuence the CDR scores
and increase these scores independent of cognition. To
conclude, we found that time to reach severe dementia
is shorter in DLB compared with AD. This, together
with the high mortality and institutionalisation rate and
caregiver burden in DLB, underlines the severe progno-
sis of this common disease. Future studies should
explore the course of other key clinical symptoms,
including motor and psychiatric symptoms. Detailed
prognostic information is vital for patients and families
and is essential to underpin accurate design and power-
ing of clinical trials, and is also essential to enable the
development of more accurate health economic models
for cost-effectiveness, which depend on conversion
between different stages of dementia severity.
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